Skip navigation
Veuillez utiliser cette adresse pour citer ce document : http://repositorio2.unb.br/jspui/handle/10482/28308
Fichier(s) constituant ce document :
Fichier TailleFormat 
ARTIGO_ClinicalTrialUniform.pdf1,91 MBAdobe PDFVoir/Ouvrir
Titre: A clinical trial for uniform multidrug therapy for leprosy patients in Brazil : rationale and design
Auteur(s): Penna, Gerson Oliveira
Pontes, Maria Araci de Andrade
Cruz, Rossilene Conceição da Silva
Gonçalves, Heitor de Sá
Penna, Maria Lúcia Fernandes
Bührer-Sékula, Samira
Assunto:: Hanseníase
Protocolo
Ensaio clínico
Drogas
Terapêutica
Date de publication: déc-2012
Editeur: Instituto Oswaldo Cruz, Ministério da Saúde
Référence bibliographique: PENNA, Gerson Oliveira et al. A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 107, supl. 1, p. 22-27, dez. 2012. DOI: https://doi.org/10.1590/S0074-02762012000900005. Disponível em: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900005&lng=en&tlng=en. Acesso em: 29 out. 2020.
Abstract: Leprosy will continue to be a public health problem for several decades. The World Health Organization (WHO) recommends that, for treatment purposes, leprosy cases be classified as either paucibacillary or multibacillary (MB). A uniform leprosy treatment regimen would simplify treatment and halve the treatment duration for MB patients. The clinical trial for uniform multidrug therapy (U-MDT) for leprosy patients (LPs) in Brazil is a randomised, open-label clinical trial to evaluate if the effectiveness of U-MDT for leprosy equals the regular regimen, to determine the acceptability of the U-MDT regimen and to identify the prognostic factors. This paper details the clinical trial methodology and patient enrolment data. The study enrolled 858 patients at two centres and 78.4% of participants were classified as MB according to the WHO criteria. The main difficulty in evaluating a new leprosy treatment regimen is that no reliable data are available for the current treatment regimen. Relapse, reaction and impaired nerve function rates have never been systematically determined, although reaction and impaired nerve function are the two major causes of nerve damage that lead to impairments and disabilities in LPs. Our study was designed to overcome the need for reliable data about the current treatment and to compare its efficacy with that of a uniform regimen.
metadata.dc.description.unidade: Faculdade de Medicina (FMD)
Licença:: Memórias do Instituto Oswaldo Cruz - (CC BY-NC) - All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Fonte: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900005&lng=en&tlng=en. Acesso em: 29 out. 2020.
DOI: https://dx.doi.org/10.1590/S0074-02762012000900005
Collection(s) :Artigos publicados em periódicos e afins

Affichage détaillé " class="statisticsLink btn btn-primary" href="/jspui/handle/10482/28308/statistics">



Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.